at least company has funding certainty and an approved product on market in EU and AUS with revenues growing.
Is FDA knockback first time around so surprising given bronchitol was initially rejected by the EMA? I'm confident pharmaxis will overcome this setback and bronchitol will gain entry to the US.
Good buying opportunity here - I am back in now. Patience on this one though.
